Language selection


Transition to and implementation of the new CMIB


The Compendium of Medicating Ingredients Brochures (CMIB) is being updated on April 1, 2018, to support new Government of Canada policies and activities to reduce antimicrobial resistance. The three key changes are:

  1. removing growth promotion claims for medically-important antimicrobial drugs
  2. moving the following medications to the prescription drug list (PDL) so they require a prescription from a veterinarian instead of being sold over the counter. These medications are:
    • bacitracin, lincomycin, neomycin, penicillin G, spectinomycin, sulphonamides, tetracycline-chlortetracycline-oxy tetracycline, tiamulin, tilmicosin, tylosin-tylvalosin, virginiamycin, or their salts or derivatives
  3. adding five medications to the CMIB so that, as of April 1, 2018, they only require a veterinary prescription before being sold. (Previously, they were approved for use in livestock feeds and listed on the PDL, and therefore required a veterinary prescription before being manufactured.) These medications are:
    • avilamycin, emamectin benzoate, florfenicol, ormetoprim, trimethoprim

The format of the CMIB has also been improved:

Transition key dates to know

April 1, 2018: Publication of the new CMIB

April 1 to November 30, 2018Footnote 1 (transition period): CFIA compliance activities

December 1, 2018: CFIA compliance activities

Note: Sequencing Guide

The sequencing guide will still be valid and available for use by feed manufacturers. Modifications will be made to the document to align with updates to the CMIB.

For more information

Learn how the CFIA is contributing to the responsible use of medically important antimicrobials in animals.

Contact your local CFIA office for more information or if you have questions.

Date modified: